What do the Bethesda system categories ASCUS (atypical squamous cells of undetermined significance), LSIL (low-grade squamous intraepithelial lesion), and HSIL (high-grade squamous intraepithelial lesion) stand for, and what are the recommended follow-up actions for each?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Bethesda System Terminology and Follow-Up Management

The Bethesda System categorizes cervical cytology results from lowest to highest cancer risk: ASCUS (atypical squamous cells of undetermined significance), LSIL (low-grade squamous intraepithelial lesion), and HSIL (high-grade squamous intraepithelial lesion), with management based on risk stratification using HPV testing and colposcopy. 1

What These Terms Mean

The Bethesda System provides standardized reporting for cervical cytology results 1:

  • ASCUS (Atypical Squamous Cells of Undetermined Significance): Cellular changes that are more abnormal than reactive but insufficient to definitively diagnose a squamous intraepithelial lesion. This represents the lowest-risk abnormal category.

  • LSIL (Low-Grade Squamous Intraepithelial Lesion): Cellular changes consistent with HPV infection and mild dysplasia (CIN 1). These lesions show koilocytosis (viral cytopathic effect) and represent transient HPV infection that often resolves spontaneously.

  • HSIL (High-Grade Squamous Intraepithelial Lesion): Cellular changes indicating moderate to severe dysplasia (CIN 2-3), representing integration of HPV genetic material with progressive mutations. These lesions carry significant risk for progression to invasive cervical cancer if untreated.

The hierarchy of cancer risk from lowest to highest is: ASCUS → LSIL → ASC-H (atypical squamous cells, cannot exclude HSIL) → HSIL → invasive carcinoma 1.

Follow-Up Management Algorithm

For ASCUS

HPV testing is the critical triage tool 1:

  • If HPV positive: Proceed to colposcopy with directed biopsies. Research shows 93.3% of ASCUS/HPV+ cases have ≥CIN 2 2.

  • If HPV negative: Return to routine screening intervals (repeat cytology in 3 years for ages 21-29, or co-testing in 5 years for ages 30-65) 1. Only 6.7% of ASCUS/HPV- cases progress to ≥CIN 2 2.

  • If HPV testing unavailable: Repeat cytology at 6 months or proceed directly to colposcopy 1.

Important caveat: Women aged 21-24 should receive more conservative management with repeat cytology rather than immediate colposcopy, even if HPV positive, due to high rates of spontaneous regression 1.

For LSIL

Management depends on age and HPV status 1:

  • Ages 25 and older with HPV positive or unknown status: Proceed to colposcopy. Data shows 96.7% of LSIL/HPV+ cases have ≥CIN 2 2.

  • Ages 25 and older with HPV negative: Co-testing at 1 year is acceptable, though colposcopy remains preferred 1.

  • Ages 21-24: Repeat cytology at 12 months rather than immediate colposcopy, as most lesions regress spontaneously in this age group 1.

The guiding principle is "similar management for similar risks" - LSIL carries higher cancer risk than ASCUS and warrants more aggressive evaluation 1.

For HSIL

Immediate colposcopy with directed biopsies is mandatory for all ages 1. Research demonstrates 59.2% histologic confirmation rate for high-grade lesions 3, and 65% show CIN 2 or worse on biopsy 4.

  • Colposcopy must visualize the entire transformation zone (adequate examination)
  • If adequate colposcopy with biopsy confirms CIN 2-3: Excisional treatment (LEEP, cold-knife conization) or ablation (laser, cryotherapy) 1
  • If inadequate colposcopy or endocervical involvement suspected: Endocervical curettage required 1

No observation period is acceptable for HSIL - the cancer risk is too high to delay intervention.

Risk-Based Stratification

The 2025 Italian guidelines emphasize risk-based thresholds for management decisions 5:

  • Immediate colposcopy threshold: CIN3+ risk warranting immediate evaluation
  • 1-year retesting threshold: Intermediate risk requiring close surveillance
  • 3-year retesting threshold: Low risk returning to routine screening

Extended HPV genotyping (identifying HPV 16/18 specifically) and p16/ki67 dual staining provide better risk stratification than cytology alone for triaging HPV-positive women 5. This approach reduces unnecessary colposcopies while maintaining sensitivity for high-grade disease.

Critical Pitfalls to Avoid

  1. Never skip HPV testing for ASCUS triage in women ≥30 years - it's the most cost-effective strategy and prevents both over- and under-treatment 1.

  2. Don't perform colposcopy on all young women (21-24) with ASCUS or LSIL - overtreatment in this age group causes unnecessary cervical trauma and pregnancy complications 1.

  3. Never delay colposcopy for HSIL - even a 6-month delay increases cancer risk unacceptably 1.

  4. Unsatisfactory cytology requires repeat testing even with negative HPV, or colposcopy for women ≥30 years 1.

  5. Immunocompromised women, DES-exposed women, and those with prior cervical cancer require more frequent screening than these standard guidelines 1.

References

1
Guideline

cervical cancer screening.

Journal of the National Comprehensive Cancer Network : JNCCN, 2014

Related Questions

For a 58-year-old patient with newly diagnosed atypical squamous cells of undetermined significance (ASC-US), should the next step be a repeat Pap smear in six months or immediate colposcopy?
What is the recommended management for a 35‑year‑old woman with a Pap smear showing low‑grade squamous intraepithelial lesion (LSIL), an endocervical curettage (ECC) involving the transformation zone (grade 6/7), and a colposcopy performed 14 months ago that demonstrated cervical intraepithelial neoplasia 1 (CIN 1)?
In a 54-year-old woman with a Pap smear showing low-grade squamous intraepithelial lesion (LSIL) and a negative human papillomavirus (HPV) test, and no known prior cervical abnormalities, what is the appropriate management?
How should atypical squamous cells (ASC‑US or ASC‑H) on cervical cytology be managed in women based on age?
In a 58-year-old woman with atypical squamous cells of undetermined significance (ASC-US) on Pap smear and a negative reflex human papillomavirus (HPV) test, why is a repeat Pap smear at six months not recommended?
When should I measure serum testosterone level if I am giving testosterone injections twice weekly (e.g., 70 mg subcutaneously on Sunday and Wednesday)?
How should I counsel a runner with a 12‑mm os trigonum causing posterior ankle impingement, and is referral to a sports‑medicine or foot‑ankle orthopaedic surgeon indicated?
What risk factors place a woman at high risk for developing cervical cancer?
What is the correct spelling of the Impella device used for cardiogenic shock?
What is the appropriate acute management and follow‑up care for a patient presenting within 24–72 hours after a sexual assault?
What are the possible causes of peripheral edema in a patient with systemic lupus erythematosus?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.